phrykt

PAVmed Inc. (PAVM): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of PAVM were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No PAVM insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PAVM short interest

Low short interest. 0.2% of PAVM shares are sold short: about 1 share in 624. Over the last 12 reports the number of shares short went down 2%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12,812 PAVM shares were sold short, 0.2% of the shares outstanding, up 0.7% from the report before. At the average daily volume of 12,354 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.16%May 15Oct 300.59%

Days to cover

1.0May 15Oct 302.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612,8120.16%+1%12,3541.0
Oct 15, 202612,7170.16%+1%27,9361.0
Sep 30, 202612,6210.16%+17%16,5361.0
Sep 15, 202610,8170.14%+36%31,5131.0
Aug 31, 20267,9390.10%-65%13,7261.0
Aug 14, 202622,6590.28%+11%82,0861.0
Jul 31, 202620,4210.32%-25%13,3341.5
Jul 15, 202627,3650.43%-19%12,5732.2
Jun 30, 202633,6500.53%+300%35,1551.0
Jun 15, 20268,4180.13%+1%17,6401.0
May 29, 20268,3010.13%-36%7,9041.1
May 15, 202613,0310.20%-26%16,2311.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

PAVmed company events

PAVmed filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 22, 2026.

  1. Oct 22, 2026AgreementLucid Diagnostics Inc., a subsidiary of PAVmed Inc., entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors, which agreements provided for the sale to the Investors of 15,000 shares of Lucid Diagnostics’ newly designated Series C Convertible… Filing
  2. Sep 10, 2026AgreementPAVmed Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company may offer and sell, from time to time through or to the Agent, shares of its common stock. Filing
  3. Aug 14, 2026ResultsReleased financial results. Filing
  4. Jun 24, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. Filing
  5. May 15, 2026ResultsReleased financial results. Filing
  6. Mar 30, 2026ResultsReleased financial results. Filing
  7. Mar 27, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. Filing
  8. Feb 4, 2026AgreementPAVmed Inc. entered into subscription agreements with certain accredited investors and, pursuant to and concurrently with the execution of the Subscription Agreements, sold to the Investors, for an aggregate purchase price of $30 million, (i) 30,000 shares of the Company’s newly designated Series D… Filing
  9. Jan 23, 2026AnnouncementPAVmed Inc. received a notification letter from the Listing Qualifications department of The Nasdaq Stock Market LLC stating that the Company had regained compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Filing
  10. Dec 30, 2025SharesChanged the rights of its shareholders. Filing
  11. Dec 5, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

PAVmed financials

Famous investors that hold PAVM

1 of the 50 well-known investors we track reported holding PAVM in their latest 13F filing. The largest position is Ken Griffin's, worth $107K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202629,095$107K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PAVM in the last 120 days.

FiledHolderFormStake
Nov 3, 2026Dols Scott V.13G/A5.8%
Nov 3, 2026Dols Scott V.13G/A5.8%
Oct 23, 2026Kallman Craig13G/A4.9%
Oct 23, 2026Kallman Craig13G/A4.9%

Questions about PAVmed Inc. (PAVM) stock

Are PAVM insiders buying or selling?

No PAVM insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in PAVM?

As of Oct 30, 2026, 12,812 PAVM shares were sold short, 0.2% of the shares outstanding, up 0.7% from the report before. At the average daily volume of 12,354 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold PAVM?

1 of the 50 well-known investors we track reported PAVM in their latest 13F filing, including Ken Griffin. The largest position is worth $107K. See all holders.

Executive pay

PAVmed's chief executive was paid a total of $1M for the year ended Dec 31, 2025, down 24% from $1.4M the year before. In the last 12 months, PAVmed's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$992KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$596KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.